P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Bibliographic Details
Main Authors:	C. Ryan, D. Brander, P. Barr, S. Tyekucheva, Y. Ren, L. Hackett, M. McDonough, K. Pena Del Aguila, M. McEwan, M. Collins, J. Abramson, E. Jacobsen, A. LaCasce, D. Fisher, J. Brown, M. Davids
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845580.45096.48

Similar Items

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
by: Rohitashva Agrawal, et al.
Published: (2020-07-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL
by: I. Solman, et al.
Published: (2022-06-01)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
by: Arnon Kater, et al.
Published: (2023-08-01)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient
by: Kim Abbegail Tan Aldecoa, et al.
Published: (2023-01-01)

IBRUTİNİB-OBİNUTUZUMAB COMBİNATİON THERAPY İN THE TREATMENT OF RELAPSED NODAL MARGİNAL ZONE LYMPHOMA: A CASE STUDY
by: Nuray Gül Açar, et al.
Published: (2023-10-01)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL
by: P. L. Zinzani, et al.
Published: (2022-06-01)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
by: Steven Le Gouill, et al.
Published: (2023-08-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
by: Subir Roy Chowdhury, et al.
Published: (2021-01-01)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
by: Barbara Eichhorst, et al.
Published: (2023-08-01)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
by: Caroline Dartigeas, et al.
Published: (2022-09-01)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
by: Alessandro Broccoli, et al.
Published: (2021-12-01)

Zantem Agnès (van), Obin Jean-Pierre, La carte scolaire. Faits, révélations, analyses
by: Bernard Delvaux
Published: (2009-04-01)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
by: Jamie B. Oughton, et al.
Published: (2017-07-01)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
by: Shaqir Qerama, et al.
Published: (2023-08-01)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
by: M. Dimopoulos, et al.
Published: (2022-06-01)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
by: McClanahan, F, et al.
Published: (2010)

Estimating Eulerian Energy Spectra from Drifters
by: J. H. LaCasce
Published: (2016-10-01)

A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL
by: Can Chen, et al.
Published: (2023-03-01)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
by: Ingo Schwaner, et al.
Published: (2023-08-01)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: J. C. Barrientos, et al.
Published: (2022-06-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
by: Kathleen L Deering, et al.
Published: (2022-01-01)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
by: Kathleen L. Deering, et al.
Published: (2022-01-01)

Baroclinic vortices over a sloping bottom
by: LaCasce, Joseph H., 1964-
Published: (2010)

P674: Gene variant spectrum in probands with familial exudative vitreoretinopathy
by: Sarah van der Ende, et al.
Published: (2024-01-01)

Obinutuzumab en el tratamiento de la glomerulonefritis membranosa PLA2R positiva resistente a tratamiento
by: Francisco José de la Prada Álvarez, et al.
Published: (2024-03-01)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
by: Petra Langerbeins, et al.
Published: (2023-08-01)

PB1881: IBRUTINIB REDUCES THE RISK OF RICHTER’S TRANSFORMATION IN PREVIOUSLY TREATED CLL PATIENTS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA
by: R. Ramadan, et al.
Published: (2022-06-01)

The Finite Size Lyapunov Exponent and the Finite Amplitude Growth Rate
by: Thomas Meunier, et al.
Published: (2021-10-01)

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
by: J. P. Sharman, et al.
Published: (2022-06-01)

Picturing Haiti: Philomé Obin, Hector Hyppolite, and the Participation of the Centre d’Art at the 4th Bienal de São Paulo (1957)
by: Bruno Pinheiro
Published: (2023-12-01)

Some problems in the theory of groups
by: McDonough, T, et al.
Published: (1972)